CENTER ID: | TogoA.00487.a |
ORGANISM: | Toxoplasma gondii ME49 |
ASSOCIATED DISEASE: | Toxoplasmosis |
CURRENT STATUS: | purified |
COMMUNITY REQUEST: | True |
NIH RISK GROUP: | 2 |
SELECT AGENT: | False |
NIH PRIORITY pathogens category: |
IIIB |
CENTER REFERENCE ID |
DOMAIN/REGION DESCRIPTION |
INFO | AA START |
AA STOP |
ORDER MATERIAL |
---|---|---|---|---|---|
TogoA.00487.a.B21.GE42561 | VSSM N-term truncation (Hortua et al) | 178 | 592 | ||
TogoA.00487.a.B41.GE42563 | vssm-khkh | 178 | 580 | ||
TogoA.00487.a.B61.GE42565 | miys | 181 | 592 |
CENTER REFERENCE ID |
DOMAIN/REGION DESCRIPTION |
INFO | AA START |
AA STOP |
ORDER MATERIAL |
---|---|---|---|---|---|
TogoA.00487.a.B21.PS38547 | VSSM N-term truncation (Hortua et al) | 178 | 592 | ||
TogoA.00487.a.B21.PS38563 | VSSM N-term truncation (Hortua et al) | 178 | 592 | ||
TogoA.00487.a.B21.PS38564 | VSSM N-term truncation (Hortua et al) | 178 | 592 |
RESOURCE | REFERENCE ID |
---|---|
EuPathDB: | ToxoDB:TGME49_210790 |
UniProt: | Q8MXD1 |
HARVESTED ON: | 7/3/2018 |
SEQUENCED ON: | 7/10/2018 |
EXPECTED MW: | 46kDa |
OBSERVED MW: | 46kDa |
ANTIBIOTIC MARKER: | ampicillin |
COUNT OF EXPRESSION COLONIES: | Good (10-50) |
TOTAL EXPRESSION LEVEL: | Moderate Expression |
SOLUBLE EXPRESSION LEVEL | Low Expression |
EXPRESSION HOST: | BL 21 (DE3) Rosetta |
SEQUENCING RESULT: | |
PERCENT IDENTITY: | data unavailable |
PERCENT COVERAGE: | data unavailable |
HARVESTED ON: | 7/3/2018 |
SEQUENCED ON: | 7/10/2018 |
EXPECTED MW: | 45kDa |
OBSERVED MW: | 46kDa |
ANTIBIOTIC MARKER: | ampicillin |
COUNT OF EXPRESSION COLONIES: | Good (10-50) |
TOTAL EXPRESSION LEVEL: | Moderate Expression |
SOLUBLE EXPRESSION LEVEL | Insoluble |
EXPRESSION HOST: | BL 21 (DE3) Rosetta |
SEQUENCING RESULT: | |
PERCENT IDENTITY: | data unavailable |
PERCENT COVERAGE: | data unavailable |
HARVESTED ON: | 7/3/2018 |
SEQUENCED ON: | 7/10/2018 |
EXPECTED MW: | 46kDa |
OBSERVED MW: | 46kDa |
ANTIBIOTIC MARKER: | ampicillin |
COUNT OF EXPRESSION COLONIES: | Good (10-50) |
TOTAL EXPRESSION LEVEL: | Moderate Expression |
SOLUBLE EXPRESSION LEVEL | Insoluble |
EXPRESSION HOST: | BL 21 (DE3) Rosetta |
SEQUENCING RESULT: | |
PERCENT IDENTITY: | 99 |
PERCENT COVERAGE: | 98 |
PURIFICATION DATe: | 12/12/2018 |
CONCENTRATION: | 2.54mg/ml |
OBSERVED MW: | 46kDa |
EXPRESSION LEVEL: | Low Expression |
PROTEIN PURIFICATION BUFFER: | SEC: 20 mM HEPES pH 7.0, 300 mM NaCl, 5% glycerol, 1 mM TCEP, 0.25mM Orotic Acid |
EXPRESSION HOST: | BL 21 (DE3) Rosetta |
VIAL COUNT (approx.): | 5 |
VIAL VOLUME: | 110µl |
PERCENT IDENTITY: | data unavailable |
PERCENT COVERAGE: | data unavailable |
PURIFICATION DATe: | 3/27/2019 |
CONCENTRATION: | 2.17mg/ml |
OBSERVED MW: | 45kDa |
EXPRESSION LEVEL: | Low Expression |
PROTEIN PURIFICATION BUFFER: | SEC: 20 mM HEPES pH 7.0, 300 mM NaCl, 5% glycerol, 0.25mM Orotic Acid, 1 mM TCEP |
EXPRESSION HOST: | BL 21 (DE3) Rosetta |
VIAL COUNT (approx.): | 1 |
VIAL VOLUME: | 155µl |
PERCENT IDENTITY: | data unavailable |
PERCENT COVERAGE: | data unavailable |
PURIFICATION DATe: | 3/27/2019 |
CONCENTRATION: | 2.54mg/ml |
OBSERVED MW: | 45kDa |
EXPRESSION LEVEL: | Low Expression |
PROTEIN PURIFICATION BUFFER: | SEC: 20 mM HEPES pH 7.0, 300 mM NaCl, 5% glycerol, 0.25mM Orotic Acid, 1 mM TCEP |
EXPRESSION HOST: | BL 21 (DE3) Rosetta |
VIAL COUNT (approx.): | 2 |
VIAL VOLUME: | 120µl |
PERCENT IDENTITY: | data unavailable |
PERCENT COVERAGE: | data unavailable |